Northwest & Ethical Investments’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.32M Sell
221,058
-149,514
-40% -$3.91M 0.12% 131
2026
Q1
$10.4M Sell
370,572
-45,490
-11% -$1.21M 0.24% 107
2025
Q4
$10.4M Sell
416,062
-148,595
-26% -$3.75M 0.23% 112
2025
Q3
$14.4M Sell
564,657
-47,286
-8% -$1.17M 0.34% 91
2025
Q2
$14.8M Buy
611,943
+402,490
+192% +$9.39M 0.37% 89
2025
Q1
$5.31M Sell
209,453
-55,619
-21% -$1.46M 0.14% 170
2024
Q4
$7.03M Buy
265,072
+1,541
+0.6% +$41.8K 0.19% 155
2024
Q3
$7.63M Buy
263,531
+7,799
+3% +$228K 0.2% 147
2024
Q2
$7.16M Buy
255,732
+19,882
+8% +$547K 0.21% 141
2024
Q1
$6.54M Sell
235,850
-154,329
-40% -$4.28M 0.19% 150
2023
Q4
$11.2M Buy
390,179
+25,533
+7% +$772K 0.35% 100
2023
Q3
$12.1M Buy
364,646
+141,058
+63% +$4.99M 0.41% 82
2023
Q2
$8.2M Buy
223,588
+65,941
+42% +$2.57M 0.26% 122
2023
Q1
$6.43M Buy
157,647
+13,767
+10% +$595K 0.21% 141
2022
Q4
$7.37M Sell
143,880
-71,620
-33% -$3.43M 0.25% 127
2022
Q3
$9.43M Buy
215,500
+10,071
+5% +$489K 0.38% 85
2022
Q2
$10.8M Buy
205,429
+79,027
+63% +$4.03M 0.4% 81
2022
Q1
$6.54M Sell
126,402
-55,181
-30% -$2.86M 0.21% 130
2021
Q4
$10.7M Buy
181,583
+111,178
+158% +$5.51M 0.32% 95
2021
Q3
$3.03M Buy
70,405
+16,111
+30% +$714K 0.1% 205
2021
Q2
$2.13M Sell
54,294
-74,370
-58% -$2.89M 0.07% 235
2021
Q1
$4.66M Buy
128,664
+40,114
+45% +$1.42M 0.16% 167
2020
Q4
$3.26M Sell
88,550
-11,124
-11% -$408K 0.12% 198
2020
Q3
$3.47M Sell
99,674
-1,162
-1% -$40.7K 0.15% 172
2020
Q2
$3.13M Buy
100,836
+4,439
+5% +$151K 0.15% 182
2020
Q1
$2.99M Sell
96,397
-78,714
-45% -$2.68M 0.17% 164
2019
Q4
$6.51M Buy
175,111
+73,424
+72% +$2.62M 0.29% 109
2019
Q3
$3.47M Buy
101,687
+4,323
+4% +$157K 0.17% 160
2019
Q2
$4M Sell
97,364
-87,600
-47% -$3.48M 0.2% 150
2019
Q1
$7.45M Buy
184,964
+6,302
+4% +$252K 0.39% 68
2018
Q4
$7.4M Buy
178,662
+21,164
+13% +$879K 0.44% 57
2018
Q3
$6.59M Buy
157,498
+2,371
+2% +$91.3K 0.41% 66
2018
Q2
$5.34M Buy
155,127
+49,774
+47% +$1.7M 0.35% 75
2018
Q1
$3.55M Buy
105,353
+41,914
+66% +$1.44M 0.24% 132
2017
Q4
$2.18M Sell
63,439
-5,892
-8% -$201K 0.14% 207
2017
Q3
$2.36M Buy
69,331
+4,501
+7% +$145K 0.15% 182
2017
Q2
$2.07M Sell
64,830
-5,966
-8% -$188K 0.14% 191
2017
Q1
$2.3M Buy
70,796
+15,715
+29% +$495K 0.16% 171
2016
Q4
$1.7M Sell
55,081
-113,612
-67% -$3.47M 0.12% 208
2016
Q3
$5.42M Buy
+168,693
New +$5.64M 0.38% 62
2015
Q2
Sell
-165,478
Closed -$5.46M 231
2015
Q1
$5.46M Sell
165,478
-1,476
-0.9% -$46.9K 0.38% 66
2014
Q4
$4.93M Buy
+166,954
New +$4.79M 0.33% 75
2013
Q4
Sell
-428,230
Closed -$11.7M 241
2013
Q3
$11.7M Buy
428,230
+20,675
+5% +$563K 0.85% 29
2013
Q2
$10.8M Buy
+407,555
New +$11.3M 0.85% 32

Other funds holding PFE

Northwest & Ethical Investments's PFE Position: Q2 2026 in Review

Northwest & Ethical Investments reduced its Pfizer (PFE) stake by 40% in Q2 2026, selling an estimated $3.91M and leaving 221,058 shares worth $5.32M. The position accounts for 0.12% of the portfolio, ranked #131.

Northwest & Ethical Investments first reported a position in PFE in Q2 2013 and has held it in 44 quarters since. The position peaked at $14.8M in Q2 2025. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Northwest & Ethical Investments held 221,058 shares of Pfizer worth $5.32M as of Q2 2026.
  • Northwest & Ethical Investments sold 149,514 Pfizer shares in Q2 2026, an estimated $3.91M.
  • Pfizer made up 0.12% of Northwest & Ethical Investments's portfolio in Q2 2026, its #131 holding.
  • Northwest & Ethical Investments first reported a position in Pfizer in Q2 2013 and has held it in 44 quarters since.
  • Northwest & Ethical Investments's Pfizer position peaked at $14.8M in Q2 2025.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.